Cleerly LABS vs Lung Density Analysis
AI Verdict
Choose Cleerly LABS if…
Choose Cleerly LABS if your primary concern is comprehensive, AI-powered analysis of coronary CT angiography to detect, quantify, and characterize atherosclerosis and stenosis. This tool is ideal for clinicians focused on personalized heart disease management, risk assessment, and tracking the progression of coronary artery disease over time to prevent heart attacks.
View Cleerly LABS →Choose Lung Density Analysis if…
Choose IMBIO's Lung Density Analysis if you require detailed, quantitative assessment and 3D visualization of lung conditions from CT scans, particularly for diagnosing and managing diseases like COPD and emphysema. It is especially well-suited for lung cancer screening programs utilizing low-dose CT scans, offering automated workflows and patient-centered reports to aid in smoking cessation counseling.
View Lung Density Analysis →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly LABS | Lung Density Analysis |
|---|---|---|
| Pricing | Varies | Unknown |
| Deployment | Cloud, On-premise | Unknown |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Lung Density AnalysisIMBIO Lung Density Analysis emphasizes fully automated workflows that integrate directly into PACS, aiming to deliver quantitative analysis and 3D visualization without requiring additional work from radiologists. While Cleerly LABS also offers a rich, interactive web-based user experience, Imbio's focus on seamless, automated integration into existing radiology workflows provides a slight edge in minimizing user intervention.
Clinical Value
Cleerly LABSCleerly LABS demonstrates strong clinical value through comprehensive plaque assessment, stenosis detection, and ischemia detection, with studies showing high diagnostic accuracy and prognostic utility for major adverse cardiovascular events. Notably, its AI algorithms have been associated with a 41% reduction in heart attacks in stable symptomatic patients in a study. IMBIO also has strong validation, but Cleerly's direct impact on patient outcomes and risk stratification provides a stronger clinical value proposition.
Pricing & Value
Cleerly LABSCleerly LABS offers transparent pricing, detailing a retail price, a discounted rate, and information regarding insurance coverage and applicable CPT codes. This transparency allows potential users to better understand and evaluate the cost and potential reimbursement. In contrast, IMBIO Lung Density Analysis requires direct contact for pricing, making it difficult to assess its value proposition upfront.
Enterprise Readiness
Lung Density AnalysisIMBIO Lung Density Analysis offers superior enterprise readiness due to its flexible deployment options, including cloud-based, locally virtualized (VM, Docker), and integration through various AI marketplaces and distribution platforms. This broad compatibility and integration potential within diverse healthcare IT environments surpasses Cleerly's cloud-based (AWS) model with an on-site proxy.
Innovation
Cleerly LABSCleerly LABS showcases significant innovation by providing a comprehensive, multi-faceted assessment of coronary artery disease, including detailed plaque characterization, stenosis, and ischemia detection from a single CCTA. Its AI-driven approach goes beyond traditional qualitative analysis to offer quantitative assessment with demonstrated prognostic value, representing a novel standard in heart disease management. IMBIO's patented PRM technology and noise reduction are also innovative, but Cleerly's holistic approach to CAD is slightly more impactful.
Support & Docs
Lung Density AnalysisIMBIO Lung Density Analysis provides more explicit and detailed information regarding its support channels, including phone, email, and an online form, with specified support hours. It also clearly states that user manuals and other product documentation are available upon request. While Cleerly offers client support, Imbio's transparency and accessibility for support and documentation are more clearly outlined.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly LABS | Lung Density Analysis |
|---|---|---|
| Tool Name | Cleerly LABS | Lung Density Analysis |
| Company | Cleerly | IMBIO |
| Description | AI-powered, FDA-cleared web-based software for comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis, aiding in personalized heart disease management. | AI-driven medical imaging software that provides quantitative analysis and 3D visualization of lung conditions from CT scans, aiding in the diagnosis and management of diseases like COPD and emphysema. It offers automated workflows and detailed reports for personalized patient care. |
| Primary Medical Focus | Coronary CT angiography (CCTA) for heart disease | CT scans for lung conditions (COPD, emphysema) |
| Key Feature 1 | AI-powered CCTA image analysis | Automated detection, visualization, and quantification of emphysema |
| Key Feature 2 | Comprehensive coronary plaque assessment (volume, type) | Validated for low-dose CT scans in lung cancer screening |
Videos
Demos, reviews, and walkthroughs featuring Cleerly LABS and Lung Density Analysis.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly LABS or Lung Density Analysis
Backers
Who funded each tool's parent company.